论文部分内容阅读
目的通过动物在体实验探讨柔红霉素预防后囊膜混浊的作用及其临床可行性。方法采用0．5～10mg·L-1柔红霉素在兔眼晶体囊外摘除术中行囊袋内灌注10min（30例），以20mg·L-1柔红霉素作维持前房灌注（1例）。通过手术显微镜及扫描电镜观察术后眼组织反应。结果随访3mo发现，随用药浓度增加，后囊膜混浊发生率及严重程度下降，未发现角膜损伤及术后葡萄膜反应，较高浓度桑红霉素应用亦未造成明显的角膜内皮细胞改变。结论本研究表明应用桑红霉素1次性眼内灌注可减少后囊膜混浊发生率、且无邻近眼组织损伤。高效。安全、简便的用药特点提示柔红霉素在后覆膜混浊预防中具有临床应用价值及可行性。
Objective To explore the role of daunorubicin in the prevention of posterior capsule opacification in animal experiments and its clinical feasibility. Methods Daunorubicin (0.5-10 mg · L -1) was injected intracapsularly for 10 minutes (30 cases) in rabbits’ extracapsular cataract extraction. An intramuscular injection of daunorubicin (20 mg · L -1) 1 case). Postoperative ocular tissue reaction was observed by surgical microscope and scanning electron microscope. Results The 3-month follow-up showed that the incidence and severity of posterior capsular opacification decreased with the increase of the drug concentration. No corneal injury and postoperative uveal reaction were found. The application of higher concentrations of safin did not result in obvious change of corneal endothelial cells. Conclusion This study shows that the application of saeghammycin once intraocular perfusion can reduce the incidence of posterior capsule opacity, and no adjacent eye tissue damage. Efficient. Safe, simple and convenient medication characteristics suggest that daunorubicin posterior capsular opacification has clinical value and feasibility.